drugset
drugset / Trial / NCT06632522

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

NCT06632522 ↗

Phase 2 Not yet recruiting 46 enrolled Beijing Tsinghua Chang Gung Hospital
NaSingle-groupOpen-labelTreatment

Summary

Clinical study of radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4.

Timeline

Start
2024-10-20
Primary completion
2025-11-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Rivoceranib Small molecule 250 mg Oral

Indications

liver cancer